Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Buyse

Showing results (71-80 of 227) with videos related to

Pageof 23
Sort By:
Therapeutic Innovation & Regulatory Science|February 9, 2024
Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical TrialsSylviane de Viron, Laura Trotta, William Steijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2019
What Does Metastasis-Free Survival Actually Mean?Christopher J Sweeney, Richard De Abreu Lourenco, Anis A Hamid, et al.
Future Oncology (London, England)|September 13, 2019
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III studyTimothy S Pardee, Sanjeev Luther, Marc Buyse, et al.
Controlled Clinical Trials|December 31, 2002
Statistical challenges in the evaluation of surrogate endpoints in randomized trialsGeert Molenberghs, Marc Buyse, Helena Geys, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2011
Progression-free survival ratio as end point for phase II trials in advanced solid tumorsMarc Buyse, Emmanuel Quinaux, Alain Hendlisz, et al.
Nature Reviews. Clinical Oncology|April 7, 2010
Biomarkers and surrogate end points--the challenge of statistical validationMarc Buyse, Daniel J Sargent, Axel Grothey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trialsJunichi Sakamoto, Yasuo Ohashi, Chikuma Hamada, et al.
Biometrics|October 3, 2014
On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpointsAriel Alonso, Wim Van der Elst, Geert Molenberghs, et al.
Statistical Methods in Medical Research|July 18, 2009
A unified framework for the evaluation of surrogate endpoints in mental-health clinical trialsGeert Molenberghs, Tomasz Burzykowski, Ariel Alonso, et al.
Biometrics|February 12, 2016
An information-theoretic approach for the evaluation of surrogate endpoints based on causal inferenceAriel Alonso, Wim Van der Elst, Geert Molenberghs, et al.
Pageof 23

Showing results (71-80 of 227) with videos related to

Sort By:
Pageof 23
Therapeutic Innovation & Regulatory Science|February 9, 2024
Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical TrialsSylviane de Viron, Laura Trotta, William Steijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2019
What Does Metastasis-Free Survival Actually Mean?Christopher J Sweeney, Richard De Abreu Lourenco, Anis A Hamid, et al.
Future Oncology (London, England)|September 13, 2019
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III studyTimothy S Pardee, Sanjeev Luther, Marc Buyse, et al.
Controlled Clinical Trials|December 31, 2002
Statistical challenges in the evaluation of surrogate endpoints in randomized trialsGeert Molenberghs, Marc Buyse, Helena Geys, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2011
Progression-free survival ratio as end point for phase II trials in advanced solid tumorsMarc Buyse, Emmanuel Quinaux, Alain Hendlisz, et al.
Nature Reviews. Clinical Oncology|April 7, 2010
Biomarkers and surrogate end points--the challenge of statistical validationMarc Buyse, Daniel J Sargent, Axel Grothey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trialsJunichi Sakamoto, Yasuo Ohashi, Chikuma Hamada, et al.
Biometrics|October 3, 2014
On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpointsAriel Alonso, Wim Van der Elst, Geert Molenberghs, et al.
Statistical Methods in Medical Research|July 18, 2009
A unified framework for the evaluation of surrogate endpoints in mental-health clinical trialsGeert Molenberghs, Tomasz Burzykowski, Ariel Alonso, et al.
Biometrics|February 12, 2016
An information-theoretic approach for the evaluation of surrogate endpoints based on causal inferenceAriel Alonso, Wim Van der Elst, Geert Molenberghs, et al.
Pageof 23